Sign Up to like & get
recommendations!
0
Published in 2018 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2018.1536538
Abstract: ABSTRACT Introduction: Despite the dramatic progress made in the treatment of patients with myelofibrosis since the introduction of the JAK1/2 inhibitor ruxolitinib, a therapeutic option that can modify the natural history of the disease and…
read more here.
Keywords:
medicine;
treatments tackle;
myelofibrosis;
novel treatments ... See more keywords